Press Tigers, Author at Iterion Therapeutics https://iteriontherapeutics.com/author/press-tigers/ Thu, 14 Sep 2023 19:49:02 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://iteriontherapeutics.com/wp-content/uploads/2023/09/cropped-Asset-1-32x32.png Press Tigers, Author at Iterion Therapeutics https://iteriontherapeutics.com/author/press-tigers/ 32 32 Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors https://pubmed.ncbi.nlm.nih.gov/32068780/#new_tab https://pubmed.ncbi.nlm.nih.gov/32068780/#new_tab#respond Tue, 28 Jul 2020 20:52:40 +0000 https://iteriontherapeutics.com/?p=877 Dyana T.Saenz, PhD, Christopher Peter Mill, PhD BA, Warren Fiskus, BSc, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

The post Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors appeared first on Iterion Therapeutics.

]]> Dyana T.Saenz, PhD, Christopher Peter Mill, PhD BA, Warren Fiskus, BSc, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

The post Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/32068780/#new_tab/feed/ 0 Iterion Therapeutics Initiates Enrollment of Phase 2a study Dose Expansion Study of Tegavivint in Patients with Desmoid Tumor https://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html#new_tab https://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html#new_tab#respond Tue, 28 Jul 2020 19:44:39 +0000 https://iteriontherapeutics.com/?p=426 Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivnt in Patients with Desmoid Tumors.

The post Iterion Therapeutics Initiates Enrollment of Phase 2a study Dose Expansion Study of Tegavivint in Patients with Desmoid Tumor appeared first on Iterion Therapeutics.

]]> Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivnt in Patients with Desmoid Tumors.

The post Iterion Therapeutics Initiates Enrollment of Phase 2a study Dose Expansion Study of Tegavivint in Patients with Desmoid Tumor appeared first on Iterion Therapeutics.

]]> https://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html#new_tab/feed/ 0 Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma https://pubmed.ncbi.nlm.nih.gov/30793158/#new_tab https://pubmed.ncbi.nlm.nih.gov/30793158/#new_tab#respond Thu, 21 Feb 2019 18:50:39 +0000 https://iteriontherapeutics.com/?p=463 Motonari Nomura, Nino Rainusso, Yi-Chien Lee, Brian Dawson, Cristian Coarfa, Ruolan Han, Jeffrey L Larson, Ryan Shuck, Lyazat Kurenbekova, Jason T Yustein.

The post Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma appeared first on Iterion Therapeutics.

]]> Motonari Nomura, Nino Rainusso, Yi-Chien Lee, Brian Dawson, Cristian Coarfa, Ruolan Han, Jeffrey L Larson, Ryan Shuck, Lyazat Kurenbekova, Jason T Yustein.

The post Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/30793158/#new_tab/feed/ 0 Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. https://pubmed.ncbi.nlm.nih.gov/30575820/#new_tab https://pubmed.ncbi.nlm.nih.gov/30575820/#new_tab#respond Fri, 21 Dec 2018 11:54:47 +0000 https://iteriontherapeutics.com/?p=206 Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

The post Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. appeared first on Iterion Therapeutics.

]]> Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN.

The post Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/30575820/#new_tab/feed/ 0 Iterion Therapeutics Initiates Phase 1 Clinical Study of Tegavivint in Patients with Desmoid Tumors https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html#new_tab https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html#new_tab#respond Wed, 05 Dec 2018 14:44:13 +0000 https://iteriontherapeutics.com/?p=1 Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase 1 clinical study of Tegavivint, its lead therapeutic candidate, in patients with desmoid tumors that are unresectable and symptomatic or progressive.

The post Iterion Therapeutics Initiates Phase 1 Clinical Study of Tegavivint in Patients with Desmoid Tumors appeared first on Iterion Therapeutics.

]]> Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase 1 clinical study of Tegavivint, its lead therapeutic candidate, in patients with desmoid tumors that are unresectable and symptomatic or progressive.

The post Iterion Therapeutics Initiates Phase 1 Clinical Study of Tegavivint in Patients with Desmoid Tumors appeared first on Iterion Therapeutics.

]]> https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html#new_tab/feed/ 0 β-catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. https://pubmed.ncbi.nlm.nih.gov/28500235/#new_tab https://pubmed.ncbi.nlm.nih.gov/28500235/#new_tab#respond Sun, 17 Sep 2017 11:58:04 +0000 https://iteriontherapeutics.com/?p=208 Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.

The post β-catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. appeared first on Iterion Therapeutics.

]]> Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.

The post β-catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma. appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/28500235/#new_tab/feed/ 0 Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-catenin Pathway Inhibitors. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00460#new_tab https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00460#new_tab#respond Thu, 13 Aug 2015 12:00:34 +0000 https://iteriontherapeutics.com/?p=212 Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.

The post Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-catenin Pathway Inhibitors. appeared first on Iterion Therapeutics.

]]> Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.

The post Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-catenin Pathway Inhibitors. appeared first on Iterion Therapeutics.

]]> https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00460#new_tab/feed/ 0 Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. https://pubmed.ncbi.nlm.nih.gov/25482131/#new_tab https://pubmed.ncbi.nlm.nih.gov/25482131/#new_tab#respond Mon, 29 Jun 2015 11:58:57 +0000 https://iteriontherapeutics.com/?p=210 Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

The post Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. appeared first on Iterion Therapeutics.

]]> Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

The post Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/25482131/#new_tab/feed/ 0